{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-074090","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2026-06-15T20:40:42+00:00","discovered_at":"2026-06-15T20:42:00.463344+00:00","generated_at":"2026-06-15T20:42:17.704849+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Coherus Oncology dismisses EY as auditor, appoints PwC effective June 12, 2026","bullets":["Dismissed Ernst & Young as auditor effective June 12, 2026; no adverse opinions or disagreements in prior periods.","Audit committee selected PricewaterhouseCoopers as new auditor for FY 2026, subject to standard client acceptance.","A material weakness in internal control over inventory reconciliations reported for FY 2024 was remediated by FY 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-074090","json":"https://secwatch.observer/filing/0001104659-26-074090.json","markdown":"https://secwatch.observer/filing/0001104659-26-074090.md","text":"https://secwatch.observer/filing/0001104659-26-074090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/0001104659-26-074090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/chrs-20260612x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:42:17.704849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a741583bde153edb6c814bfa1de036edfd44cc4f","claim":"Coherus Oncology, Inc. dismissed Ernst & Young LLP as its auditor.","evidence_excerpt":"On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with dismissal effective as of such date.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/0001104659-26-074090-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Ernst & Young LLP"},{"label":"Successor","value":"PricewaterhouseCoopers LLP"}],"fact_type":"auditor_change"},{"claim_id":"f44a54b89df6d1ce7d7c8636b502c03498cb52bc","claim":"Coherus Oncology, Inc. engaged PricewaterhouseCoopers LLP as its auditor.","evidence_excerpt":"On June 12, 2026, the Audit Committee of the Board of Directors of the Company selected PricewaterhouseCoopers LLP (“PwC”) to be appointed to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/0001104659-26-074090-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"PricewaterhouseCoopers LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}